Literature DB >> 30997508

Timeliness of Human Immunodeficiency Virus Diagnosis and Antiretroviral Treatment Initiation in the Era of Universal Testing and Treatment.

McKaylee M Robertson1,2, Sarah L Braunstein3, Donald R Hoover4, Sheng Li2, Denis Nash1,2.   

Abstract

BACKGROUND: We describe the timing of human immunodeficiency virus (HIV) diagnosis and antiretroviral treatment (ART) initiation after implementation of universal testing and treatment policies in New York City (NYC).
METHODS: Using NYC population-based HIV registry data for persons with HIV diagnosed from 2012 through 2015 and followed up through June 2017, we examined trends in the proportion with diagnosis soon after HIV infection (ie, with CD4 cell count ≥500/μL or with acute HIV infection) and used Kaplan-Meier plots and proportional hazards regression to examine the timing of ART initiation after diagnosis.
RESULTS: Among 9987 NYC residents with HIV diagnosed from 2012 to 2015, diagnosis was early in 35%, and 87% started ART by June 2017. The annual proportion of persons with early diagnosis did not increase appreciably (35% in 2012 vs 37% in 2015; P = .08). By 6 months after diagnosis, 62%, 67%, 72% and 77% of persons with HIV diagnosed in 2012, 2013, 2014, or 2015, respectively, had started ART, with median (interquartile range) times to ART initiation of 3.34 (1.34-12.75), 2.62 (1.28-10.13), 2.16 (1.15-7.11), and 2.03 (1.11-5.61) months, respectively.
CONCLUSIONS: Although recommendations for ART initiation on diagnosis are increasingly being implemented, the findings of the current study suggest that immediate treatment initiation is not universal. Continued efforts are needed to expand and better target HIV testing to promote earlier diagnosis.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV diagnosis; HIV treatment initiation; HIV viral load Suppression; universal test and treat

Mesh:

Substances:

Year:  2019        PMID: 30997508     DOI: 10.1093/infdis/jiz148

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Estimates of the Time From Seroconversion to Antiretroviral Therapy Initiation Among People Newly Diagnosed With Human Immunodeficiency Virus From 2006 to 2015, New York City.

Authors:  McKaylee M Robertson; Sarah L Braunstein; Donald R Hoover; Sheng Li; Denis Nash
Journal:  Clin Infect Dis       Date:  2020-11-05       Impact factor: 9.079

2.  Impact of an HIV Care Coordination Program on the Timeliness of Viral Suppression and Immune Recovery Among Clients Newly Diagnosed with HIV.

Authors:  McKaylee M Robertson; Kate Penrose; Denis Nash; Graham Harriman; Sarah L Braunstein; Bruce Levin; Mary K Irvine
Journal:  AIDS Behav       Date:  2020-04

3.  Timeliness of antiretroviral therapy initiation in the era before universal treatment.

Authors:  Nikolina Bogdanić; Liam Bendig; Davorka Lukas; Šime Zekan; Josip Begovac
Journal:  Sci Rep       Date:  2021-05-18       Impact factor: 4.379

4.  Factors Influencing Rapid Antiretroviral Therapy Initiation at Four eThekwini Clinics, KwaZulu-Natal, South Africa.

Authors:  Sabina M Govere; Chester Kalinda; Moses J Chimbari
Journal:  AIDS Behav       Date:  2021-11-15

Review 5.  Reaching the second 90: the strategies for linkage to care and antiretroviral therapy initiation.

Authors:  Bridget A Bunda; Ingrid V Bassett
Journal:  Curr Opin HIV AIDS       Date:  2019-11       Impact factor: 4.283

6.  Durable Viral Suppression Among People with HIV and Problem Substance Use in the Era of Universal Antiretroviral Treatment.

Authors:  Margaret M Paschen-Wolff; Aimee N C Campbell; Susan Tross; Tse-Hwei Choo; Martina Pavlicova; Sarah Braunstein; Rachael Lazar; Christine Borges; Michael Castro; Hayley Berg; Graham Harriman; Robert H Remien; Don Des Jarlais
Journal:  AIDS Behav       Date:  2021-07-30

7.  A province-wide HIV initiative to accelerate initiation of treatment-as-prevention and virologic suppression in British Columbia, Canada: a population-based cohort study.

Authors:  Ni Gusti Ayu Nanditha; Xinzhe Dong; Hiwot M Tafessu; Lu Wang; Michelle Lu; Rolando Barrios; Julio S G Montaner; Viviane D Lima
Journal:  CMAJ Open       Date:  2022-01-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.